Prognostic Value of GLUT-1 Expression in Oral Squamous Cell Carcinoma: A Prisma-compliant Meta-analysis

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2016 Nov 10

PMID 27828852

Citations 19

Authors

Chen-Xi Li

Jia-Lin Sun

Zhong-Cheng Gong

Zhao-Quan Lin

Hui Liu

Affiliations

Soon will be listed here.

Abstract

Background: A variety of studies have evaluated the correlation between glucose transporter-1 (GLUT-1) expression and prognosis of oral squamous cell carcinoma (OSCC); however, the results were inconsistent and inconclusive. A meta-analysis was performed to assess the prognostic significance of GLUT-1 in OSCC.

Methods: Electronic databases of PubMed, Embase, and Web of Science were searched for relevant studies. The last search was updated on July 2016. Odds ratio (OR) and 95% confidence interval (CI) were pooled to evaluate the relationship between GLUT-1 and clinical features and hazard ratio (HR) and 95% CI were combined to measure the effect of GLUT-1 on overall survival (OS). P value < 0.05 was considered as statistically significant.

Results: A total of 13 studies with 1301 subjects were included for meta-analysis. The pooled data showed that high GLUT-1 expression was associated with advanced tumor stages (n = 7, OR = 2.99, 95% CI: 2.01-4.46, P < 0.001), higher tumor grade (n = 5, OR = 3.34, 95%CI: 1.12-9.94, P = 0.031), tumor size (n = 5, OR = 3.36, 95%CI: 2.04-5.51, P < 0.001), lymph node metastasis (n = 5, OR = 3.15, 95%CI: 1.89-5.25, P < 0.001), tobacco use (n = 3, OR = 2.18, 95%CI: 1.18-4.01, P = 0.013), and distant metastasis (n = 2, OR = 3.06, 95%CI: 1.19-7.9, P = 0.02). Furthermore, increased GLUT-1 expression was also correlated with shorter OS (n = 8, HR = 1.88, 95%CI: 1.51-2.33, P < 0.001). No significant publication bias was detected in this meta-analysis.

Conclusion: GLUT-1 overexpression was in connection with aggressive clinical features and worse OS in OSCC. However, further studies are still needed to verify whether GLUT-1 could serve as a prognostic biomarker for OSCC.

Citing Articles

Aspartate-β-hydroxylase and hypoxia marker expression in head and neck carcinomas: implications for HPV-associated tumors.

Smahelova J, Pokryvkova B, Stovickova E, Grega M, Vencalek O, Smahel M Infect Agent Cancer. 2024; 19(1):26.

PMID: 38858774 PMC: 11163809. DOI: 10.1186/s13027-024-00588-1.

Tumour response to hypoxia: understanding the hypoxic tumour microenvironment to improve treatment outcome in solid tumours.

Bigos K, Quiles C, Lunj S, Smith D, Krause M, Troost E Front Oncol. 2024; 14:1331355.

PMID: 38352889 PMC: 10861654. DOI: 10.3389/fonc.2024.1331355.

Hallmarks of Cancer Applied to Oral and Oropharyngeal Carcinogenesis: A Scoping Review of the Evidence Gaps Found in Published Systematic Reviews.

Gonzalez-Moles M, Warnakulasuriya S, Lopez-Ansio M, Ramos-Garcia P Cancers (Basel). 2022; 14(15).

PMID: 35954497 PMC: 9367256. DOI: 10.3390/cancers14153834.

Assessment of the association of OCT3/4 with GLUT1 and CD105 in oral squamous cell carcinoma using dual immunohistochemistry.

Derakhshan S, Mahdavi N, Khoozestani N, Nasr Esfahani B, Heidarian F, Rahrotaban S BMC Oral Health. 2022; 22(1):300.

PMID: 35854304 PMC: 9297621. DOI: 10.1186/s12903-022-02332-w.

CD147 promotes glucose metabolism, invasion and metastasis via PI3K/AKT pathway in oral squamous cell carcinomas.

Huang Y, Xu J, Xu Y, Li L, Zheng M Transl Cancer Res. 2022; 8(4):1486-1496.

PMID: 35116891 PMC: 8798969. DOI: 10.21037/tcr.2019.07.50.

References

Mori Y, Tsukinoki K, Yasuda M, Miyazawa M, Kaneko A, Watanabe Y . Glucose transporter type 1 expression are associated with poor prognosis in patients with salivary gland tumors. Oral Oncol. 2006; 43(6):563-9. DOI: 10.1016/j.oraloncology.2006.06.006. View

Han M, Lee H, Cho K, Kim J, Roh J, Choi S . Role of FDG-PET as a biological marker for predicting the hypoxic status of tongue cancer. Head Neck. 2011; 34(10):1395-402. DOI: 10.1002/hed.21945. View

Vasconcelos M, Vasconcelos R, Oliveira D, Santos E, Pereira Pinto L, da Silveira E . Distribution of Hypoxia-Inducible Factor-1α and Glucose Transporter-1 in Human Tongue Cancers. J Oral Maxillofac Surg. 2015; 73(9):1753-60. DOI: 10.1016/j.joms.2015.03.013. View

Angadi V, Angadi P . GLUT-1 immunoexpression in oral epithelial dysplasia, oral squamous cell carcinoma, and verrucous carcinoma. J Oral Sci. 2015; 57(2):115-22. DOI: 10.2334/josnusd.57.115. View

Xie S, Liu Y, Qiao X, Hua R, Wang K, Shan X . What is the Prognostic Significance of Ki-67 Positivity in Oral Squamous Cell Carcinoma?. J Cancer. 2016; 7(7):758-67. PMC: 4860791. DOI: 10.7150/jca.14214. View

Kang S, Chun Y, Hur M, Lee H, Kim Y, Hong S . Clinical significance of glucose transporter 1 (GLUT1) expression in human breast carcinoma. Jpn J Cancer Res. 2002; 93(10):1123-8. PMC: 5926879. DOI: 10.1111/j.1349-7006.2002.tb01214.x. View

Merrall N, Plevin R, Gould G . Growth factors, mitogens, oncogenes and the regulation of glucose transport. Cell Signal. 1993; 5(6):667-75. DOI: 10.1016/0898-6568(93)90028-k. View

Rogers S, Brown J, Woolgar J, Lowe D, Magennis P, Shaw R . Survival following primary surgery for oral cancer. Oral Oncol. 2008; 45(3):201-11. DOI: 10.1016/j.oraloncology.2008.05.008. View

Harshani J, Yeluri S, Guttikonda V . Glut-1 as a prognostic biomarker in oral squamous cell carcinoma. J Oral Maxillofac Pathol. 2015; 18(3):372-8. PMC: 4409181. DOI: 10.4103/0973-029X.151318. View

10.

Kawamura T, Kusakabe T, Sugino T, Watanabe K, Fukuda T, Nashimoto A . Expression of glucose transporter-1 in human gastric carcinoma: association with tumor aggressiveness, metastasis, and patient survival. Cancer. 2001; 92(3):634-41. DOI: 10.1002/1097-0142(20010801)92:3<634::aid-cncr1364>3.0.co;2-x. View

11.

Parmar M, Torri V, Stewart L . Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1999; 17(24):2815-34. DOI: 10.1002/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8. View

12.

Kunkel M, Reichert T, Benz P, Lehr H, Jeong J, Wieand S . Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer. 2003; 97(4):1015-24. DOI: 10.1002/cncr.11159. View

13.

Qian J, Wenguang X, Zhiyong W, Yuntao Z, Wei H . Hypoxia inducible factor: a potential prognostic biomarker in oral squamous cell carcinoma. Tumour Biol. 2016; 37(8):10815-20. DOI: 10.1007/s13277-016-4976-3. View

14.

Rojas Ayala F, Rocha R, Carvalho K, Carvalho A, da Cunha I, Lourenco S . GLUT1 and GLUT3 as potential prognostic markers for Oral Squamous Cell Carcinoma. Molecules. 2010; 15(4):2374-87. PMC: 6257354. DOI: 10.3390/molecules15042374. View

15.

Haber R, Rathan A, Weiser K, Pritsker A, Itzkowitz S, Bodian C . GLUT1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis. Cancer. 1998; 83(1):34-40. DOI: 10.1002/(sici)1097-0142(19980701)83:1<34::aid-cncr5>3.0.co;2-e. View

16.

Brown R, Wahl R . Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. Cancer. 1993; 72(10):2979-85. DOI: 10.1002/1097-0142(19931115)72:10<2979::aid-cncr2820721020>3.0.co;2-x. View

17.

Grimm M, Munz A, Teriete P, Nadtotschi T, Reinert S . GLUT-1(+)/TKTL1(+) coexpression predicts poor outcome in oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014; 117(6):743-53. DOI: 10.1016/j.oooo.2014.02.007. View

18.

Joost H, Thorens B . The extended GLUT-family of sugar/polyol transport facilitators: nomenclature, sequence characteristics, and potential function of its novel members (review). Mol Membr Biol. 2002; 18(4):247-56. DOI: 10.1080/09687680110090456. View

19.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(7):e1000097. PMC: 2707599. DOI: 10.1371/journal.pmed.1000097. View

20.

Warnakulasuriya S . Global epidemiology of oral and oropharyngeal cancer. Oral Oncol. 2008; 45(4-5):309-16. DOI: 10.1016/j.oraloncology.2008.06.002. View